Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Hemophilia B. Currently, gene therapies are gaining popularity due to their potential to cure this disease and also the anticipated one-time infusion. Apart from this, increased focus on prophylactic treatment, increase in usage of extended half-life therapies, and anticipated entry of premium-priced novel hemophilia B treatments will also contribute to the growth of the market.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia B market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hemophilia B drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hemophilia B treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hemophilia B: An Overview
Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding and bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia types is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, which is a genetic disorder caused by missing or defective factor IX, a clotting protein.
Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.
The two main symptoms are bleeding for longer than normal and bruising easily. With this disease, even a small bump on the head can be serious. Hemophilia B can range from mild to moderate to severe. Individuals with mild hemophilia have factor IX levels between 5 and 40% of normal; those with moderate hemophilia have factor levels from 1 to 5% of normal; and individuals with severe hemophilia have factor levels <1% of normal.
Hemophilia B Market Key Facts
-
Among the 7MM, the US accounts for ~50% of the overall market size of Hemophilia B in 2020.
-
Among the EU-5 countries, France accounts for the highest market size for Hemophilia B followed by the United Kingdom
-
In the United States, the total number of prevalent cases of Hemophilia B was 4,134 in the year 2020.
-
In the year 2020, the total prevalent cases of Hemophilia B were 5,408 in EU-5.
-
In Japan, the total number of prevalent cases of Hemophilia B was 1,198 in the year 2020.
-
Moderate and severe account for ~75% of the Hemophilia B patient pool. In the 7MM, there were around 8,054 moderate and severe Hemophilia B cases in 2020.
-
In the 7MM, approximately 5% of Hemophilia B cases develop inhibitors, i.e., 537 patients with inhibitors in 2020. In addition to this, 95% of the Hemophilia B cases were observed without inhibitors. The number of cases for both categories will increase during the study period.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hemophilia B pipeline therapies. It also thoroughly assesses the Hemophilia B market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hemophilia B drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hemophilia B Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hemophilia B epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hemophilia B epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hemophilia B Epidemiology, Segmented as –
-
Total Diagnosed Prevalent Pool of Hemophilia B [2019–2032]
-
Treated Prevalent Pool of Hemophilia B [2019–2032]
-
Severity-specific Prevalent Pool of Hemophilia B [2019–2032]
-
Prevalent population of Hemophilia B with or without Inhibitors [2019–2032]
Hemophilia B Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hemophilia B market or expected to be launched during the study period. The analysis covers the Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hemophilia B drugs based on their sale and market share.
The report also covers the Hemophilia B pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hemophilia B companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hemophilia B Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/hemophilia-b-market
Hemophilia B Companies Actively Working in the Therapeutics Market Include
-
Alnylam Pharmaceuticals
-
ApcinteX Ltd
-
Bioverativ Therapeutics
-
CSL Behring
-
Freeline Therapeutics
-
Genzyme, a Sanofi Company
-
HEMA Biologics
-
LFB Pharmaceuticals
-
Novo Nordisk
-
Pfizer
-
Sangamo Therapeutics
-
Sobi
-
Spark Therapeutics
-
UniQure Biopharma B.V.
And Many Others
Emerging and Marketed Hemophilia B Therapies Covered in the Report Include:
-
Alprolix: Bioverativ Therapeutics/Sobi
-
AMT-060: UniQure Biopharma B.V.
-
Concizumab (NN7415): Novo Nordisk
-
Concizumab: Novo Nordisk
-
Etranacogene dezaparvovec (AMT-061): UniQure Biopharma B.V./ CSL Behring
-
Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
-
Fitusiran: Genzyme, a Sanofi Company/ Alnylam Pharmaceuticals
-
FLT180a: Freeline Therapeutics
-
Idelvion: CSL Behring
-
Marstacimab (PF-06741086): Pfizer
-
Rebinyn (Nonacog beta pegol): Novo Nordisk
-
SB-FIX: Sangamo Therapeutics
-
SerpinPC: ApcinteX Ltd
-
Sevenfact (coagulation factor VIIa [recombinant]-jncw): HEMA Biologics/LFB Pharmaceuticals
-
Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/hemophilia-b-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hemophilia B Competitive Intelligence Analysis
4. Hemophilia B Market Overview at a Glance
5. Hemophilia B Disease Background and Overview
6. Hemophilia B Patient Journey
7. Hemophilia B Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hemophilia B Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia B Unmet Needs
10. Key Endpoints of Hemophilia B Treatment
11. Hemophilia B Marketed Therapies
12. Hemophilia B Emerging Drugs and Latest Therapeutic Advances
13. Hemophilia B Seven Major Market Analysis
14. Attribute Analysis
15. Hemophilia B Market Outlook (In US, EU5, and Japan)
16. Hemophilia B Companies Active in the Market
17. Hemophilia B Access and Reimbursement Overview
18. KOL Views on the Hemophilia B Market
19. Hemophilia B Market Drivers
20. Hemophilia B Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hemophilia-b-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Bronchial Hyperreactivity Market
“Bronchial Hyperreactivity Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Bronchial Hyperreactivity market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bronchial Hyperreactivity market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices